Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
暂无分享,去创建一个
Y. Tanigawara | K. Itoh | Y. Sasaki | T. Igarashi | H. Fujii | H. Minami | T. Ohtsu | N. Uchiyama‐Kokubu | T. Aizawa | Torn Watanabe | Yoshinori Uda
[1] T. Uchiumi,et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.
[2] Y. Sugiyama,et al. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[3] D. Ross,et al. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). , 1999, Anticancer research.
[4] J. Beijnen,et al. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein , 1999, British Journal of Cancer.
[5] D. Cohen,et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[6] D. Breimer,et al. Effect of the Mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice. , 1998, The Journal of pharmacology and experimental therapeutics.
[7] S. Urien,et al. Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. , 1998, British journal of clinical pharmacology.
[8] J. Beijnen,et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.
[9] H. Kusuhara,et al. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. , 1997, The Journal of pharmacology and experimental therapeutics.
[10] G. Giaccone,et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] D. Keppler,et al. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. , 1997, The Biochemical journal.
[12] E. Estey,et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Sonneveld,et al. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. , 1996, Leukemia.
[14] B. Sikic,et al. Pharmacological considerations in the modulation of multidrug resistance. , 1996, European journal of cancer.
[15] N. Bleehen,et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Borst,et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.
[17] W. Wilson,et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Meijer,et al. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. , 1995, Biochimica et biophysica acta.
[19] J. Crowley,et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study , 1995, Cancer.
[20] D. Keppler,et al. Differential inhibition by cyclosporins of primary‐active ATP‐dependent transporters in the hepatocyte canalicular membrane , 1993, FEBS letters.
[21] R. Schilsky,et al. Modulation of vinblastine resistance with cyclosporine: A phase I study , 1993, Clinical pharmacology and therapeutics.
[22] W. Dalton,et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Edmonson,et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Sonneveld,et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin , 1992, The Lancet.
[25] I. Roninson,et al. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.
[26] B. Chauffert,et al. Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. , 1990, British Journal of Cancer.
[27] C. Benz,et al. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M C Willingham,et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[29] I. Pastan,et al. Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.
[30] Y. Ostchega,et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Alberts,et al. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. , 1986, Cancer research.
[32] K. Kawamura,et al. [Comparative studies on the pharmacokinetics between THP and adriamycin in the same patients]. , 1986, Gan to kagaku ryoho. Cancer & chemotherapy.
[33] T. Tsuruo,et al. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. , 1984, Cancer research.
[34] T. Tsuruo,et al. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. , 1983, Cancer research.
[35] T. Tsuruo,et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.
[36] A. Smith,et al. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. , 1998, Journal of the National Cancer Institute.
[37] Fischer,et al. 多剤耐性修飾剤バルスポダール(PSC 833)はヒトチトクロームP450 3Aにより代謝される 薬物間相互作用の関与と主代謝物の薬理活性 , 1998 .
[38] Hitoshi Sato,et al. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats , 1996, Cancer Chemotherapy and Pharmacology.
[39] T. Tsuruo,et al. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. , 1995, Acta oncologica.
[40] C. Gavériaux. SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier , 1991 .
[41] M. Melamed,et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[42] T. Grogan,et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. , 1989, Blood.
[43] I. Pastan,et al. Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.